RE-BVS – Piemonte Repository

Sfoglia per AUTORE
ARTALE S
Collezione AO Cuneo

Items : 5

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. in Breast care (Basel, Switzerland) / Breast Care (Basel). 2020 Feb;15(1):30-37. doi: 10.1159/000495469. Epub 2019 Apr 17.

2020
AO Cuneo

Mustacchi G; Pronzato P; Torri V; Marchetti P; Montemurro F; Riccardi F; Romagnoli E; Bisagni G; Livi L; Natoli C; Donadio M; Biganzoli L; Del Mastro L; Clivio L; Giordano M; Frassoldati A; Scavelli C; Ferzi A; Schirone A; Palumbo R; Gebbia V; Fabi A; Santini D; Turletti A; Porpiglia M; Atzori F; Blasi L; De Laurentiis M; Artale S; et alii...

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213. eCollection 2018 Oct 2.

2018
ASL Città di Torino
AO Cuneo

Clivio L; Torri On Behalf Of The Eva Study Group V; Frassoldati A; Scavelli C; Palumbo R; Ferzi A; Schirone A; Cursano MC; Fabi A; Gebbia V; Benedetto C; Atzori F; Turletti A; Blasi L; Piezzo M; Artale S; Mentuccia L; La Verde N; Bianchi G; Musolino A; Vici P; Maur M; Pistelli M; Garrone O; Generali D; Zambelli A; Febbraro A; Arcangeli V; Diodati L; et alii...

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431. eCollection 2018 Nov 30.

2018
ASL Città di Torino
AO Cuneo

Torri V; Frassoldati A; Clivio L; Scavelli C; Ferzi A; Palumbo R; Gebbia V; Schirone A; Fabi A; Benedetto C; Cursano MC; Turletti A; Atzori F; Artale S; Blasi L; Piezzo M; Bianchi G; Maur M; La Verde N; Mentuccia L; Vici P; Musolino A; Pistelli M; Garrone O; Generali D; Zambelli A; Febbraro A; Arcangeli V; Diodati L; et alii...

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Aug 7;9(61):31877-31887. doi: 10.18632/oncotarget.25874. eCollection 2018 Aug 7.

2018
ASL Città di Torino
AO Cuneo

Torri On Behalf Of The Eva Study Group V; Clivio L; Scavelli C; Frassoldati A; Ferzi A; Palumbo R; Gebbia V; Schirone A; Fabi A; Cursano MC; Turletti A; Benedetto C; Atzori F; Piezzo M; Artale S; Blasi L; La Verde N; Bianchi G; Maur M; Mentuccia L; Vici P; Musolino A; Garrone O; Pistelli M; Zambelli A; Febbraro A; Generali D; Diodati L; Arcangeli V; et alii...

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. in Breast (Edinburgh, Scotland) / Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13.

2017
AO Cuneo
ASL Città di Torino

Clivio L; Zambelli A; Blasi L; Torri V; Sartori D; Scavelli C; Schirone A; Turletti A; Vici P; Valerio MR; Palumbo R; Pistelli M; Musolino A; Porpiglia M; Arcangeli V; Artale S; Atzori F; Ballerio A; Bianchi GV; Moretti G; Maur M; Michelotti A; La Verde N; Generali D; Gebbia V; Garrone O; Fumagalli A; Frassoldati A; Ficorella C; et alii...